Logo image of SCPH

SCPHARMACEUTICALS INC (SCPH) Stock Price, Quote, News and Overview

NASDAQ:SCPH - Nasdaq - US8106481059 - Common Stock - Currency: USD

5.48  +0.1 (+1.86%)

SCPH Quote, Performance and Key Statistics

SCPHARMACEUTICALS INC

NASDAQ:SCPH (7/23/2025, 10:22:12 AM)

5.48

+0.1 (+1.86%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High5.65
52 Week Low1.94
Market Cap289.29M
Shares52.79M
Float39.93M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO11-17 2017-11-17


SCPH short term performance overview.The bars show the price performance of SCPH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

SCPH long term performance overview.The bars show the price performance of SCPH in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30

The current stock price of SCPH is 5.48 USD. In the past month the price increased by 40.47%. In the past year, price increased by 8.91%.

SCPHARMACEUTICALS INC / SCPH Daily stock chart

SCPH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 57.02 743.59B
JNJ JOHNSON & JOHNSON 16.68 401.27B
NVO NOVO-NORDISK A/S-SPONS ADR 18.76 306.79B
NVS NOVARTIS AG-SPONSORED ADR 13.17 225.62B
AZN ASTRAZENECA PLC-SPONS ADR 16.57 223.46B
MRK MERCK & CO. INC. 10.61 207.56B
PFE PFIZER INC 7.88 143.81B
SNY SANOFI-ADR 10.88 120.78B
BMY BRISTOL-MYERS SQUIBB CO 6.63 99.07B
GSK GSK PLC-SPON ADR 8.38 75.42B
ZTS ZOETIS INC 25.27 67.74B
TAK TAKEDA PHARMACEUTIC-SP ADR 64.02 46.00B

About SCPH

Company Profile

SCPH logo image scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

Company Info

SCPHARMACEUTICALS INC

25 Burlington Mall Road, Suite 203

Burlington MASSACHUSETTS 01803 US

CEO: John H. Tucker

Employees: 163

SCPH Company Website

SCPH Investor Relations

Phone: 16175170730

SCPHARMACEUTICALS INC / SCPH FAQ

What is the stock price of SCPHARMACEUTICALS INC today?

The current stock price of SCPH is 5.48 USD. The price increased by 1.86% in the last trading session.


What is the ticker symbol for SCPHARMACEUTICALS INC stock?

The exchange symbol of SCPHARMACEUTICALS INC is SCPH and it is listed on the Nasdaq exchange.


On which exchange is SCPH stock listed?

SCPH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SCPHARMACEUTICALS INC stock?

11 analysts have analysed SCPH and the average price target is 15.91 USD. This implies a price increase of 190.36% is expected in the next year compared to the current price of 5.48. Check the SCPHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SCPHARMACEUTICALS INC worth?

SCPHARMACEUTICALS INC (SCPH) has a market capitalization of 289.29M USD. This makes SCPH a Micro Cap stock.


How many employees does SCPHARMACEUTICALS INC have?

SCPHARMACEUTICALS INC (SCPH) currently has 163 employees.


Is SCPHARMACEUTICALS INC (SCPH) expected to grow?

The Revenue of SCPHARMACEUTICALS INC (SCPH) is expected to grow by 105.36% in the next year. Check the estimates tab for more information on the SCPH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SCPHARMACEUTICALS INC (SCPH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SCPHARMACEUTICALS INC (SCPH) stock pay dividends?

SCPH does not pay a dividend.


When does SCPHARMACEUTICALS INC (SCPH) report earnings?

SCPHARMACEUTICALS INC (SCPH) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of SCPHARMACEUTICALS INC (SCPH)?

SCPHARMACEUTICALS INC (SCPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.91).


What is the Short Interest ratio of SCPHARMACEUTICALS INC (SCPH) stock?

The outstanding short interest for SCPHARMACEUTICALS INC (SCPH) is 3.84% of its float. Check the ownership tab for more information on the SCPH short interest.


SCPH Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to SCPH. When comparing the yearly performance of all stocks, SCPH is one of the better performing stocks in the market, outperforming 93.92% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SCPH Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SCPH. SCPH may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SCPH Financial Highlights

Over the last trailing twelve months SCPH reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS decreased by -29.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -99.8%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-2.78%
Sales Q2Q%92.59%
EPS 1Y (TTM)-29.05%
Revenue 1Y (TTM)138.02%

SCPH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to SCPH. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 43.9% and a revenue growth 105.36% for SCPH


Ownership
Inst Owners58.37%
Ins Owners6.08%
Short Float %3.84%
Short Ratio4.44
Analysts
Analysts83.64
Price Target15.91 (190.33%)
EPS Next Y43.9%
Revenue Next Year105.36%